SRSF6

Serine/arginine-rich splicing factor 6 · Q13247 · SRSF6 on Sugi Atlas →

734 patent compounds predicted against SRSF6, 649 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Indacaterol (SCHEMBL48098)	1.00	1/20
Indacaterol (SCHEMBL159597)	1.00	1/20
Indacaterol (SCHEMBL4186345)	1.00	1/20
Indacaterol (SCHEMBL29350045)	1.00	1/20
Indacaterol (SCHEMBL29367297)	1.00	1/20
Indacaterol (SCHEMBL867570)	0.98	1/20
Indacaterol (SCHEMBL867571)	0.98	1/20
Indacaterol (SCHEMBL3664612)	0.98	1/20
Indacaterol (SCHEMBL4012026)	0.98	1/20
Indacaterol (SCHEMBL4012030)	0.98	1/20
Indacaterol (SCHEMBL4013062)	0.96	1/20
Indacaterol (SCHEMBL4014822)	0.96	1/20
Indacaterol (SCHEMBL362019)	0.92	1/20
Indacaterol (SCHEMBL4007697)	0.92	1/20
Indacaterol (SCHEMBL4007713)	0.92	1/20
Indacaterol (SCHEMBL4008829)	0.92	1/20
Indacaterol (SCHEMBL4008836)	0.92	1/20
Indacaterol (SCHEMBL4009719)	0.92	1/20
Indacaterol (SCHEMBL4012540)	0.92	1/20
Indacaterol (SCHEMBL4012550)	0.92	1/20

Clinical trials — most relevant to SRSF6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer	PHASE2	COMPLETED
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)	PHASE1/PHASE2	SUSPENDED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
SRSF2 Gene Mutation in Patients With t-MDS/AML	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping	nan	UNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs	nan	UNKNOWN
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders	nan	COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Research for Individualized Therapeutics in Rare Genetic Disease	nan	ENROLLING_BY_INVITATION
Mechanisms of Cell Death in Spinal Muscular Atrophy	nan	COMPLETED
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN)	nan	UNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)	nan	RECRUITING
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscular Atrophy Patients	nan	UNKNOWN
RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2	nan	COMPLETED
Vascular Endothelial Factor Gene Polymorphism in Preeclampsia	nan	COMPLETED
Clinical Study of Spinal Muscular Atrophy	nan	COMPLETED
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SRSF6 binder may also engage these)

Protein	Name	Similarity
G3V6S8	—	1.000	G3V6S8 →
Q3B7L6	—	1.000	Q3B7L6 →
Q3TWW8	—	0.999	Q3TWW8 →
P26686	—	0.980	P26686 →
Q13243	—	0.978	Q13243 →
O35326	—	0.974	O35326 →
Q09167	—	0.974	Q09167 →
Q8VE97	—	0.972	Q8VE97 →
Q08170	—	0.969	Q08170 →
Q3T106	—	0.953	Q3T106 →
SRSF7	Serine/arginine-rich splicing factor 7	0.950	landscape →
Q23121	—	0.950	Q23121 →
Q13595	—	0.947	Q13595 →
Q6PFR5	—	0.945	Q6PFR5 →
Q10021	—	0.944	Q10021 →
Q5NVM8	—	0.942	Q5NVM8 →
Q15287	—	0.942	Q15287 →
TRA2B	Transformer-2 protein homolog beta	0.940	landscape →
Q6PG31	—	0.940	Q6PG31 →
P62996	—	0.940	P62996 →
Q5XG24	—	0.940	Q5XG24 →
Q3ZBT6	—	0.939	Q3ZBT6 →
Q23120	—	0.939	Q23120 →
Q4R5N1	—	0.939	Q4R5N1 →
P62997	—	0.939	P62997 →
Q99M28	—	0.939	Q99M28 →
Q6AYK1	—	0.938	Q6AYK1 →
Q66II8	—	0.938	Q66II8 →
Q6PDU1	—	0.936	Q6PDU1 →
A2RVS6	—	0.936	A2RVS6 →